K
Keith A. Baggerly
Researcher at University of Texas MD Anderson Cancer Center
Publications - 193
Citations - 59407
Keith A. Baggerly is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Cancer & Ovarian cancer. The author has an hindex of 65, co-authored 192 publications receiving 50803 citations. Previous affiliations of Keith A. Baggerly include University of Texas Health Science Center at Houston & Harvard University.
Papers
More filters
Journal ArticleDOI
Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments
TL;DR: Concerns suggest that much of the structure uncovered in SELDI proteomic spectra from serum experiments could be due to artifacts of sample processing, not to the underlying biology of cancer.
Journal ArticleDOI
Steps toward mapping the human vasculature by phage display
Wadih Arap,Mikhail G. Kolonin,Martin Trepel,Johanna Lahdenranta,Marina Cardó-Vila,Ricardo J. Giordano,Paul J. Mintz,Peter U. Ardelt,Virginia J. Yao,Claudia I. Vidal,Limor Chen,Anne L. Flamm,Heli Valtanen,Lisa M. Weavind,Marshall E. Hicks,Raphael E. Pollock,Gregory H. Botz,Corazon D. Bucana,Erkki Koivunen,Dolores J. Cahill,Patricia Troncoso,Keith A. Baggerly,Rebecca D. Pentz,Kim Anh Do,Christopher J. Logothetis,Renata Pasqualini +25 more
TL;DR: This large-scale screening of a peptide library in a patient indicates that the tissue distribution of circulating peptides is nonrandom and may have broad implications for the development of targeted therapies.
Journal ArticleDOI
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes
Hiroko Masuda,Keith A. Baggerly,Ying Wang,Ya Zhang,Ana M. Gonzalez-Angulo,Funda Meric-Bernstam,Vicente Valero,Brian D. Lehmann,Jennifer A. Pietenpol,Gabriel N. Hortobagyi,W. Fraser Symmans,Naoto T. Ueno +11 more
TL;DR: The clinical relevancy of the 7-subtype classification of triple-negative breast cancer reported by Lehmann and colleagues is confirmed, and may spur innovative personalized medicine strategies for patients with TNBC.
Journal ArticleDOI
Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites.
TL;DR: A wide range of methods exists to detect genomic DNA methylation, in-cluding approaches to detect genome-wide and gene-specific methylation lev-els, and recently, high-throughput methods to detect site-spe-cific methylation have been developed using the TaqMan.
Journal ArticleDOI
New tumor markers: CA125 and beyond
Robert C. Bast,Donna Badgwell,Zhimin Lu,Rebecca T. Marquez,Daniel G. Rosen,Jiaxin Liu,Keith A. Baggerly,Edward N. Atkinson,Steven J. Skates,Zhen Zhang,Anna Lokshin,Usha Menon,Ian Jacobs,Karen H. Lu +13 more
TL;DR: CA125 (MUC16) has provided a useful serum tumor marker for monitoring response to chemotherapy, detecting disease recurrence, distinguishing malignant from benign pelvic masses, and potentially improving clinical trial design.